Taken together, our data support a key role for the YAP co-activator and its molecular interaction partners, i.e., TEAD transcription factors, in acquired resistance to trastuzumab in breast cancer, suggesting that these molecules could be potent druggable targets to prevent treatment resistance to anti-HER2 targeted therapy. This evidence concerns the gene ERBB2 and breast cancer.